Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Early recurrence after hepatectomy for colorectal liver metastases: the definition and predictive factors

Date

19 Dec 2015

Session

Poster presentation 1

Presenters

Katsunori Imai

Citation

Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523

Authors

K. Imai1, M. Allard1, C. Castro Benitez1, E. Vibert1, A. Sa Cunha1, D. Cherqui1, D. Castaing1, H. Bismuth1, T. Beppu2, H. Baba2, R. Adam1

Author affiliations

  • 1 Centre Hépato-biliaire, Hopital Paul Brousse, F-94804 - Villejuif/FR
  • 2 Department Of Gastroenterological Surgery, Kumamoto University, 860-8556 - Kumamoto/JP
More

Resources

Aim/Background

Although early recurrence is one of the prognostic factors of poor survival after surgery for colorectal liver metastases (CRLM), the definition of early recurrence has been determined arbitrarily. The aim of this study was to determine the optimal cut-off point of early recurrence and elucidate its predictive factors after hepatectomy for CRLM.

Methods

From a total cohort of 987 patients who underwent curative hepatectomy for CRLM between 1990 and 2012, 846 patients who had a minimum follow-up period of 24 months were eligible for this study. Minimum P value approach of survival after initial recurrence was used to determine the optimal cut-off points for the definition of early recurrence. Predictive factors of early recurrence and prognostic factors of survival in patients with early and late recurrence were analyzed.

Results

The 5-year overall and disease-free survival rate were 50.2 and 17.8%, respectively. For 667 patients (79%) who developed recurrence, the optimal cut-off point of early recurrence was determined to be 8 months after hepatectomy. The impact of early recurrence on survival was demonstrated mainly in patients who received preoperative chemotherapy. Among the 691 patients who received preoperative chemotherapy, recurrence was observed in 562 patients (81%), and the survival in patients with early recurrence was significantly worse than that with late recurrence (5-year survival: 18.5% vs. 53.4%, P < 0.0001). Multivariate logistic analysis identified age ≤ 57 (relative risk (RR) 1.79, P = 0.0022), preoperative chemotherapy lines > 1 (RR 1.58, P = 0.03), disease progression during last-line chemotherapy (RR 2.18, P = 0.024), tumor number > 3 (RR 1.81, P = 0.0014), and carbohydrate antigen 19-9 > 60 U/mL (RR 2.21, P = 0.0003) as independent predictive factors of early recurrence. Salvage surgery for recurrence improved survival significantly, even in patients with early recurrence (5-year survival: 38.8% vs. 4.2%, P < 0.0001).

Conclusions

For better selection of patients who could really benefit from surgery, preoperative prediction of early recurrence is crucial. Salvage surgery should be taken into account proactively even for early recurrence.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings